Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Friedreich's ataxia gene therapies - Adverum Biotechnologies

Next Previous
Drug Profile

Research programme: Friedreich's ataxia gene therapies - Adverum Biotechnologies

Alternative Names: AAVrh 10

Latest Information Update: 15 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Annapurna Therapeutics; Institut de Genetique et de Biologie Moleculaire et Cellulaire
  • Developer AAVLife; Institut de Genetique et de Biologie Moleculaire et Cellulaire
  • Class Gene therapies
  • Mechanism of Action Frataxin expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Friedreich's ataxia

Most Recent Events

  • 09 Dec 2025 Adverum Biotechnologies has been acquired by Eli Lilly and Company
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Friedreich's ataxia in France (IV, Injection)
  • 01 Apr 2018 Adverum Biotechnologies terminates an exclusive license agreement with REGENXBIO for Friedreich's ataxia using NAV®rAAVrh10 vector delivery

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top